An Indian Multicentric Open Label Prospective Phase IV Study to Evaluate Safety and Efficacy of Trastuzumab in Her2 Positive, Node Positive or High Risk Node Negative Breast Cancer as Part of a Treatment Regimen Consisting of Doxorubicin, Cyclophosphamide, With Either Docetaxel or Paclitaxel (AC-TH) or Docetaxel and Carboplatin (TCH)

Trial Profile

An Indian Multicentric Open Label Prospective Phase IV Study to Evaluate Safety and Efficacy of Trastuzumab in Her2 Positive, Node Positive or High Risk Node Negative Breast Cancer as Part of a Treatment Regimen Consisting of Doxorubicin, Cyclophosphamide, With Either Docetaxel or Paclitaxel (AC-TH) or Docetaxel and Carboplatin (TCH)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Trastuzumab (Primary) ; Carboplatin; Cyclophosphamide; Docetaxel; Docetaxel; Doxorubicin; Paclitaxel
  • Indications Advanced breast cancer; Early breast cancer
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 16 Jun 2017 Planned End Date changed from 8 Dec 2021 to 28 Dec 2021.
    • 16 Jun 2017 Planned primary completion date changed from 8 Dec 2021 to 28 Dec 2021.
    • 08 May 2017 Planned End Date changed from 1 Feb 2020 to 8 Dec 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top